Zydus Lifesciences vs Lupin: share price, P/E, ROE and financials compared
Zydus Lifesciences
Lupin
Zydus Lifesciences and Lupin at a glance
Zydus Lifesciences and Lupin are both listed in Healthcare. Zydus Lifesciences is the larger by market cap, at ₹1.2L Cr against ₹90,914 Cr for Lupin (1.3 times as large). On valuation, Lupin has the lower P/E (17.5× against 28.6×) and the lower price-to-book (3.78× against 4.29×). On returns and margins, Lupin has the higher ROCE (28.3% against 19.0%), the higher ROE (23.9% against 14.7%) and the higher operating margin (28.9% against 26.2%). Over three years, Lupin has faster 3-year sales growth (+19.1% against +16.5% a year) and faster 3-year profit growth (+131.4% against +37.0% a year). Lupin carries less debt for its equity, with a debt-to-equity of 0.26× against 0.46×.
Key metrics, side by side
| Metric | Zydus LifesciencesZYDUSLIFE | LupinLUPIN |
|---|---|---|
| Price (₹) | 1,197.90 | 1,988.10 |
| Market cap (₹ Cr) | 1,19,491 | 90,914 |
| P/E | 28.6× | 17.5× (the lower figure, shaded) |
| P/B | 4.29× | 3.78× (the lower figure, shaded) |
| Dividend yield, trailing | 0.08% | 0.91% (the higher figure, shaded) |
| ROE | 14.7% | 23.9% (the higher figure, shaded) |
| ROCE | 19.0% | 28.3% (the higher figure, shaded) |
| Operating margin (OPM) | 26.2% | 28.9% (the higher figure, shaded) |
| Net margin (NPM) | 13.8% | 16.9% (the higher figure, shaded) |
| Sales CAGR 3Y | +16.5% | +19.1% (the higher figure, shaded) |
| Profit CAGR 3Y | +37.0% | +131.4% (the higher figure, shaded) |
| Debt to equity | 0.46× | 0.26× (the lower figure, shaded) |
| Interest cover | 19.1× (the higher figure, shaded) | 17.7× |
| Net profit TTM (₹ Cr) | – | 5,206 |
| 1Y return | +22.8% (the higher figure, shaded) | −0.5% |
| Promoter holding | – | 46.84% |
Zydus Lifesciences vs Lupin: common questions
Which is bigger, Zydus Lifesciences or Lupin?
By market cap, Zydus Lifesciences is bigger at ₹1.2L Cr, against ₹90,914 Cr for Lupin (prices as of 6 Nov 2026).
Which has a lower P/E ratio, Zydus Lifesciences or Lupin?
Zydus Lifesciences trades at a P/E of 28.6× and Lupin at 17.5×. Lupin has the lower P/E. P/E is the share price divided by earnings per share; it varies a lot between industries and with growth, so it says little on its own.
Which has a higher ROE, Zydus Lifesciences or Lupin?
Zydus Lifesciences reports a return on equity of 14.7% and Lupin 23.9%. Lupin has the higher ROE. ROE is net profit as a share of shareholders’ equity.
Which is growing faster, Zydus Lifesciences or Lupin?
Over the last three years: Sales grew +16.5% a year at Zydus Lifesciences and +19.1% at Lupin, so Lupin grew sales faster; profit grew +37.0% a year at Zydus Lifesciences and +131.4% at Lupin, so Lupin grew profit faster. Past growth doesn’t predict future growth.